AR009958A1 - Composiciones adyuvantes; vacunas formuladas con dichas composiciones; el uso de dichas composiciones en la preparacion de vacunas y procedimiento parapreparar dichas vacunas. - Google Patents
Composiciones adyuvantes; vacunas formuladas con dichas composiciones; el uso de dichas composiciones en la preparacion de vacunas y procedimiento parapreparar dichas vacunas.Info
- Publication number
- AR009958A1 AR009958A1 ARP970104569A ARP970104569A AR009958A1 AR 009958 A1 AR009958 A1 AR 009958A1 AR P970104569 A ARP970104569 A AR P970104569A AR P970104569 A ARP970104569 A AR P970104569A AR 009958 A1 AR009958 A1 AR 009958A1
- Authority
- AR
- Argentina
- Prior art keywords
- vaccines
- compositions
- preparation
- formulated
- preparing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
- C12N2740/11034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Se trata de composiciones adyuvantes, formuladas con alumbre, fracciones de saponinas inmunologicamente activas, y un esterol, particularmente colesterol.De preferencia, se trata de saponinas provenientes de la corteza de Quillaja SaponariaMolin a, tal como la fraccion Q21. También se proponen vacunas queincluyen dichas composiciones adyuvantes, para el tratamiento de enfermos de cancer o el tratamiento profilactico de infecciones. También se reivindica lapreparacion de dichasvacunas y l a preparacion de las composiciones adyuvantes mencionadas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9620795.6A GB9620795D0 (en) | 1996-10-05 | 1996-10-05 | Vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
AR009958A1 true AR009958A1 (es) | 2000-05-17 |
Family
ID=10800990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970104569A AR009958A1 (es) | 1996-10-05 | 1997-10-03 | Composiciones adyuvantes; vacunas formuladas con dichas composiciones; el uso de dichas composiciones en la preparacion de vacunas y procedimiento parapreparar dichas vacunas. |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0939650A1 (es) |
JP (1) | JP2001501640A (es) |
KR (1) | KR20000048866A (es) |
CN (1) | CN1238696A (es) |
AR (1) | AR009958A1 (es) |
AU (1) | AU714930B2 (es) |
BR (1) | BR9711853A (es) |
CA (1) | CA2267191A1 (es) |
CO (1) | CO4910170A1 (es) |
CZ (1) | CZ116799A3 (es) |
GB (1) | GB9620795D0 (es) |
HU (1) | HUP9904549A3 (es) |
IL (1) | IL128985A0 (es) |
NO (1) | NO991524L (es) |
NZ (1) | NZ334734A (es) |
PL (1) | PL332633A1 (es) |
TR (1) | TR199900729T2 (es) |
WO (1) | WO1998015287A1 (es) |
ZA (1) | ZA978868B (es) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE435661T1 (de) * | 1997-08-29 | 2009-07-15 | Antigenics Inc | Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel |
GB9718901D0 (en) * | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
GB9817052D0 (en) * | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
TR200101055T2 (tr) * | 1998-10-16 | 2001-09-21 | Smithkline Beecham Biologicals S.A. | Adjuvan sistemler ve aşılar |
AU769539B2 (en) | 1999-01-29 | 2004-01-29 | Zoetis Services Llc | Adjuvants for use in vaccines |
GB9909077D0 (en) * | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
ES2228497T3 (es) | 1999-04-19 | 2005-04-16 | Glaxosmithkline Biologicals S.A. | Composicion adyuvante que comprende saponina y un oligonucleotido inmunoestimulante. |
GB9921147D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
CN100358863C (zh) | 1999-09-24 | 2008-01-02 | 日本农药株式会社 | 芳族二酰胺衍生物或其盐、农艺组合物及其使用方法 |
EP1227837B1 (en) | 1999-10-22 | 2008-05-21 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
AU772617B2 (en) * | 1999-11-19 | 2004-05-06 | Csl Limited | Vaccine compositions |
US6905712B2 (en) | 1999-12-08 | 2005-06-14 | Statens Veterinarmedicinska Anstalt | Vaccine adjuvants comprising ginseng plant extract and added aluminum salt |
WO2001041802A1 (en) * | 1999-12-08 | 2001-06-14 | Statens Veterinärmedicinska Anstalt | Vaccine adjuvants comprising ginseng plant extract and added aluminium salt |
ES2276788T3 (es) | 2000-05-10 | 2007-07-01 | Sanofi Pasteur Limited | Polipeptidos inmunogenos codificados por minigenes mage y sus utilizaciones. |
PT2266603E (pt) | 2000-10-18 | 2012-11-02 | Glaxosmithkline Biolog Sa | Vacinas tumorais |
US20040096463A1 (en) * | 2001-02-23 | 2004-05-20 | Nathalie Garcon | Novel vaccine |
CA2438942A1 (en) * | 2001-02-23 | 2002-09-26 | Glaxosmithkline Biologicals S.A. | Influenza vaccine formulations for intradermal delivery |
GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
GB0123580D0 (en) * | 2001-10-01 | 2001-11-21 | Glaxosmithkline Biolog Sa | Vaccine |
JP2005533855A (ja) | 2002-07-24 | 2005-11-10 | インターツェル・アクチェンゲゼルシャフト | 病原性ウイルスからの別のリーディングフレームによりコードされる抗原 |
JP2006504687A (ja) | 2002-09-13 | 2006-02-09 | インターツェル・アクチェンゲゼルシャフト | C型肝炎ウイルスペプチドの単離方法 |
EP1569515A4 (en) | 2002-10-23 | 2006-04-26 | Glaxosmithkline Biolog Sa | MALARIA vaccine method |
US20070041998A1 (en) * | 2003-03-24 | 2007-02-22 | Intercell Ag | Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses |
CA2517673C (en) | 2003-03-24 | 2013-08-13 | Intercell Ag | Improved vaccines for preventing viral infection |
GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
GB0503337D0 (en) | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
GB0513421D0 (en) | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
GB0519871D0 (en) | 2005-09-30 | 2005-11-09 | Secr Defence | Immunogenic agents |
US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
ES2420829T3 (es) | 2005-11-04 | 2013-08-27 | Novartis Vaccines And Diagnostics S.R.L. | Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular |
TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
ES2707499T3 (es) | 2005-12-22 | 2019-04-03 | Glaxosmithkline Biologicals Sa | Vacuna de conjugado de polisacárido neumocócico |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
EP1998802A2 (en) | 2006-03-30 | 2008-12-10 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
MX2009000650A (es) | 2006-07-18 | 2009-07-02 | Secretary Of The Army The Unit | Vacunas para malaria. |
US8323664B2 (en) | 2006-07-25 | 2012-12-04 | The Secretary Of State For Defence | Live vaccine strains of Francisella |
CA2669209C (en) * | 2006-11-20 | 2016-01-26 | Duecom Ab | Use of lipid containing particles comprising quillaja saponins for the treatment of cancer |
EA021391B1 (ru) | 2007-03-02 | 2015-06-30 | Глаксосмитклайн Байолоджикалс С.А. | Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор |
RS54349B1 (en) | 2007-06-26 | 2016-02-29 | Glaxosmithkline Biologicals S.A. | VACCINE CONTAINING STREPTOCOCCUS PNEUMONIAE Capsular POLYSACCHARIDE CONJUGATES |
BRPI0815199A2 (pt) | 2007-08-13 | 2015-03-31 | Glaxosmithkline Biolog Sa | Uso de um antígeno derivado da proteína circunsporozóite de plasmodium falciparum |
ES2626634T3 (es) | 2007-12-19 | 2017-07-25 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Formas solubles de la glucoproteína F del virus de Hendra y Nipah y usos de la misma |
GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
GB0900455D0 (en) | 2009-01-13 | 2009-02-11 | Secr Defence | Vaccine |
GB0901423D0 (en) | 2009-01-29 | 2009-03-11 | Secr Defence | Treatment |
GB0901411D0 (en) | 2009-01-29 | 2009-03-11 | Secr Defence | Treatment |
DK2396032T3 (en) | 2009-02-10 | 2016-12-19 | Seqirus Uk Ltd | Influenza vaccines with reduced amounts of squalene |
NO2403507T3 (es) | 2009-03-05 | 2018-07-21 | ||
GB0906234D0 (en) | 2009-04-14 | 2009-05-20 | Secr Defence | Vaccine |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
AU2011231574A1 (en) | 2010-03-26 | 2012-10-11 | Glaxosmithkline Biologicals S.A. | HIV vaccine |
US20130259948A1 (en) | 2010-09-21 | 2013-10-03 | National Institute Of Immunology | Spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles |
MX354752B (es) | 2010-09-27 | 2018-03-20 | Janssen Vaccines & Prevention Bv | Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. |
DK2758432T3 (da) | 2011-09-16 | 2019-06-03 | Ucb Biopharma Sprl | Neutraliserende antistoffer mod hovedtoksinerne TcdA og TcdB fra Clostridium difficile |
US20130122038A1 (en) | 2011-11-14 | 2013-05-16 | The United States Of America As Represented By The Secretary Of The Department | Heterologous prime-boost immunization using measles virus-based vaccines |
WO2015092710A1 (en) | 2013-12-19 | 2015-06-25 | Glaxosmithkline Biologicals, S.A. | Contralateral co-administration of vaccines |
WO2018037045A1 (en) | 2016-08-23 | 2018-03-01 | Glaxosmithkline Biologicals Sa | Fusion peptides with antigens linked to short fragments of invariant chain (cd74) |
GB201614799D0 (en) | 2016-09-01 | 2016-10-19 | Glaxosmithkline Biologicals Sa | Compositions |
US11466292B2 (en) | 2016-09-29 | 2022-10-11 | Glaxosmithkline Biologicals Sa | Compositions and methods of treatment |
US10695424B2 (en) | 2016-12-07 | 2020-06-30 | Glaxosmithkline Biologicals S.A. | Method of making a liposome composition |
GB201620968D0 (en) | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
IE20190084A3 (en) * | 2017-05-30 | 2023-07-19 | Glaxosmithkline Biologicals Sa | Novel methods for manufacturing an adjuvant |
GB201721068D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
CN112638936A (zh) | 2018-06-12 | 2021-04-09 | 葛兰素史密丝克莱恩生物有限公司 | 腺病毒多核苷酸和多肽 |
MX2021001479A (es) | 2018-08-07 | 2021-04-28 | Glaxosmithkline Biologicals Sa | Novedosos procesos y vacunas. |
WO2020128012A1 (en) | 2018-12-21 | 2020-06-25 | Glaxosmithkline Biologicals Sa | Methods of inducing an immune response |
JP2022524007A (ja) | 2019-03-05 | 2022-04-27 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | B型肝炎免疫化レジメンおよび組成物 |
US20230109193A1 (en) * | 2021-10-02 | 2023-04-06 | Massachusetts Institute Of Technology | Synergistic Combination of Alum and Non-Liposome, Non-Micelle Particle Vaccine Adjuvants |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL9002314A (nl) * | 1990-10-23 | 1992-05-18 | Nederlanden Staat | Immunogene complexen, in het bijzonder iscoms. |
US5585103A (en) * | 1991-07-25 | 1996-12-17 | Idec Pharmaceutical Corporation | Induction of cytotoxic T-lymphocyte responses |
WO1994022476A1 (en) * | 1993-03-29 | 1994-10-13 | Pfizer Inc. | Multicomponent clostridial vaccines using saponin adjuvants |
UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
-
1996
- 1996-10-05 GB GBGB9620795.6A patent/GB9620795D0/en active Pending
-
1997
- 1997-09-30 KR KR1019990702874A patent/KR20000048866A/ko not_active Application Discontinuation
- 1997-09-30 CN CN97180166A patent/CN1238696A/zh active Pending
- 1997-09-30 CA CA002267191A patent/CA2267191A1/en not_active Abandoned
- 1997-09-30 NZ NZ334734A patent/NZ334734A/xx unknown
- 1997-09-30 CZ CZ991167A patent/CZ116799A3/cs unknown
- 1997-09-30 BR BR9711853A patent/BR9711853A/pt not_active Application Discontinuation
- 1997-09-30 AU AU47812/97A patent/AU714930B2/en not_active Ceased
- 1997-09-30 JP JP10517196A patent/JP2001501640A/ja active Pending
- 1997-09-30 IL IL12898597A patent/IL128985A0/xx unknown
- 1997-09-30 TR TR1999/00729T patent/TR199900729T2/xx unknown
- 1997-09-30 PL PL97332633A patent/PL332633A1/xx unknown
- 1997-09-30 HU HU9904549A patent/HUP9904549A3/hu unknown
- 1997-09-30 WO PCT/EP1997/005578 patent/WO1998015287A1/en not_active Application Discontinuation
- 1997-09-30 EP EP97910430A patent/EP0939650A1/en not_active Withdrawn
- 1997-10-03 ZA ZA978868A patent/ZA978868B/xx unknown
- 1997-10-03 AR ARP970104569A patent/AR009958A1/es unknown
- 1997-10-03 CO CO97057863A patent/CO4910170A1/es unknown
-
1999
- 1999-03-29 NO NO991524A patent/NO991524L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO991524D0 (no) | 1999-03-29 |
NO991524L (no) | 1999-03-29 |
HU9904549A (en) | 2000-05-28 |
CN1238696A (zh) | 1999-12-15 |
CZ116799A3 (cs) | 1999-08-11 |
CO4910170A1 (es) | 2000-04-24 |
TR199900729T2 (xx) | 1999-07-21 |
JP2001501640A (ja) | 2001-02-06 |
PL332633A1 (en) | 1999-09-27 |
AU714930B2 (en) | 2000-01-13 |
WO1998015287A1 (en) | 1998-04-16 |
NZ334734A (en) | 2000-05-26 |
IL128985A0 (en) | 2000-02-17 |
HUP9904549A3 (en) | 2001-06-28 |
AU4781297A (en) | 1998-05-05 |
CA2267191A1 (en) | 1998-04-16 |
BR9711853A (pt) | 1999-08-24 |
GB9620795D0 (en) | 1996-11-20 |
KR20000048866A (ko) | 2000-07-25 |
EP0939650A1 (en) | 1999-09-08 |
ZA978868B (en) | 1999-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR009958A1 (es) | Composiciones adyuvantes; vacunas formuladas con dichas composiciones; el uso de dichas composiciones en la preparacion de vacunas y procedimiento parapreparar dichas vacunas. | |
EA200801307A1 (ru) | Вакцинные композиции, содержащие сапониновый адъювант | |
NO20005051L (no) | Adjuvantsammensetninger | |
BR0312472A (pt) | Prepração de uma composição compreendendo uma mistura de complexos de iscom e uso da dita composição | |
AR001686A1 (es) | Una composición vacuna un proceso para prepararla y su uso para la fabricación de una vacuna | |
FI971498A0 (fi) | Saponiinivalmisteet ja niiden käyttö iskomeissa | |
ATE116993T1 (de) | Saponin-hilfsmittel. | |
DK209088A (da) | Medicinpraeparater, deres fremstilling og anvendelse | |
AU2002338832A1 (en) | Vaccine | |
AR008799A1 (es) | Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento | |
IL276661B2 (en) | Immunogenic preparation containing staphylococcal antigens | |
PT792165E (pt) | Composicoes imunogenicas | |
AU2821200A (en) | Matrix protein compositions for grafting | |
AR023536A1 (es) | Vacunas | |
WO2002038168A3 (de) | Verwendung von selektin-bindenden wirkstoffen zur behandlung von entzündlichen- und tumor-erkrankungen | |
AR010568A1 (es) | Polipeptido, composicion de vacuna, uso del polipeptido en la fabricacion de una composicion, y metodo para producir en un mamifero una respuestainmuno-protectora contra la infeccion de helicobacter pylori | |
BR0212834A (pt) | Formulações e uso das mesmas | |
YU37402A (sh) | Vakcina za lečenje upale prostate i benigne prostatne hiperplazije, koja obuhvata sojeve lactobacillus | |
ATE155041T1 (de) | Rectale pharmazeutische zubereitung fuer die behandlung von prostataanschwellung | |
BR0016092A (pt) | Composto, uso de um composto kit para contracepção hormonal em um macho, e, método de tratamento |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |